CMRX Chimerix
- 0.988
- +0.018+1.83%
- 0.990
- +0.003+0.25%
Chimerix News
Buy Rating Justified by Chimerix's Upcoming Catalysts and Strong Financials
Strong Buy Rating for Chimerix on Robust Financials and Promising Drug Pipeline
Chimerix's Strong Financials and Promising ONC201 Developments Merit Buy Rating
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), DENTSPLY SIRONA (XRAY) and Karuna Therapeutics (KRTX)
Chimerix Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Chimerix (CMRX)
Analysts' Top Healthcare Picks: Chimerix (CMRX), MoonLake Immunotherapeutics (MLTX)
Buy Rating Affirmed for Chimerix Amid Progress in Dordaviprone's Phase III Study and Strong Financial Outlook
Analysts' Top Healthcare Picks: Chimerix (CMRX), ImmunoGen (IMGN)
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), Rani Therapeutics Holdings (RANI) and Autolus Therapeutics (AUTL)
Joseph Thome's Buy Rating for Chimerix: An Analysis of Strategic Decision-Making and Potential Growth
JonesTrading Sticks to Their Buy Rating for Chimerix (CMRX)
Chimerix Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
Chimerix Analyst Ratings
H.C. Wainwright Remains a Buy on Chimerix (CMRX)
Robert W. Baird Keeps Their Buy Rating on Chimerix (CMRX)
Chimerix Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Humana (HUM), Intellia Therapeutics (NTLA) and Chimerix (CMRX)
JonesTrading Sticks to Their Buy Rating for Chimerix (CMRX)
Analysis
Price Target
No Data
